Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
Letrozole vs observation for HR positive breast cancer

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 31.05.15
Views: 2110

Dr Nicholas Zdenkowski - University of Newcastle, Newcastle, Australia

Dr Zdenkowski talks to ecancertv at ASCO 2015 about the final analysis of a randomised comparison of letrozole versus observation as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive breast cancer after completion of prior AET.

The results show that in postmenopausal women who had completed four or more years of AET for hormone receptor positive breast cancer showed significantly reduced the incidence of late invasive breast cancer events.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation